Cargando…
Chordomas and chondrosarcomas of the skull base: treatment and outcome analysis in a consecutive case series of 24 patients
BACKGROUND: We present our 9-year consecutive case series of skull base chordomas and chondrosarcomas from a UK tertiary referral centre, discussing treatments offered and outcomes. This was carried out to improve understanding around current treatment and to better inform the management of future p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945343/ https://www.ncbi.nlm.nih.gov/pubmed/33750413 http://dx.doi.org/10.1186/s12957-021-02178-6 |
_version_ | 1783662845306601472 |
---|---|
author | Metcalfe, Christopher Muzaffar, Jameel Kulendra, Kevin Sanghera, Paul Shaw, Simon Shad, Amjad Saravanappa, Natarajan Paluzzi, Alessandro Ahmed, Shahzada |
author_facet | Metcalfe, Christopher Muzaffar, Jameel Kulendra, Kevin Sanghera, Paul Shaw, Simon Shad, Amjad Saravanappa, Natarajan Paluzzi, Alessandro Ahmed, Shahzada |
author_sort | Metcalfe, Christopher |
collection | PubMed |
description | BACKGROUND: We present our 9-year consecutive case series of skull base chordomas and chondrosarcomas from a UK tertiary referral centre, discussing treatments offered and outcomes. This was carried out to improve understanding around current treatment and to better inform the management of future patients. METHODS: Consecutive case series over a 9-year period (2007–2016). Retrospective data analysis from the electronic skull base multidisciplinary team database and the digital patient records at a UK tertiary referral centre RESULTS: Twenty-four patients were identified (11 chordomas, 13 chondrosarcomas, mean age 52). Nineteen had proton beam therapy (PBT) postoperatively; two had intensity-modulated radiotherapy; two had no further treatment. One patient was lost to follow-up. All chordomas were resected via a transnasal endoscopic approach. Of the 19 patients undergoing resection with PBT, 13 were disease free at latest follow-up, and six patients had local recurrence, of which two died (mean follow up 7.4 years). Of the three patients treated with surgery then IMRT/TomoTherapy, one died 4 years post-treatment, and the other two are alive after 4 and 5 years of follow-up respectively. Of the two patients treated with surgery alone, one was lost to follow-up, and the other is alive after more than 8 years. Chondrosarcoma 5-year survival was 91.6%, and chordoma 4-year survival was 75%. CONCLUSION: Skull base chordomas and chondrosarcomas can be challenging to resect, and most cases require adjuvant therapy to achieve control. Where complete resection is not possible, it is critical to undertake sufficient resection to permit high-dose radiation. |
format | Online Article Text |
id | pubmed-7945343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79453432021-03-10 Chordomas and chondrosarcomas of the skull base: treatment and outcome analysis in a consecutive case series of 24 patients Metcalfe, Christopher Muzaffar, Jameel Kulendra, Kevin Sanghera, Paul Shaw, Simon Shad, Amjad Saravanappa, Natarajan Paluzzi, Alessandro Ahmed, Shahzada World J Surg Oncol Research BACKGROUND: We present our 9-year consecutive case series of skull base chordomas and chondrosarcomas from a UK tertiary referral centre, discussing treatments offered and outcomes. This was carried out to improve understanding around current treatment and to better inform the management of future patients. METHODS: Consecutive case series over a 9-year period (2007–2016). Retrospective data analysis from the electronic skull base multidisciplinary team database and the digital patient records at a UK tertiary referral centre RESULTS: Twenty-four patients were identified (11 chordomas, 13 chondrosarcomas, mean age 52). Nineteen had proton beam therapy (PBT) postoperatively; two had intensity-modulated radiotherapy; two had no further treatment. One patient was lost to follow-up. All chordomas were resected via a transnasal endoscopic approach. Of the 19 patients undergoing resection with PBT, 13 were disease free at latest follow-up, and six patients had local recurrence, of which two died (mean follow up 7.4 years). Of the three patients treated with surgery then IMRT/TomoTherapy, one died 4 years post-treatment, and the other two are alive after 4 and 5 years of follow-up respectively. Of the two patients treated with surgery alone, one was lost to follow-up, and the other is alive after more than 8 years. Chondrosarcoma 5-year survival was 91.6%, and chordoma 4-year survival was 75%. CONCLUSION: Skull base chordomas and chondrosarcomas can be challenging to resect, and most cases require adjuvant therapy to achieve control. Where complete resection is not possible, it is critical to undertake sufficient resection to permit high-dose radiation. BioMed Central 2021-03-09 /pmc/articles/PMC7945343/ /pubmed/33750413 http://dx.doi.org/10.1186/s12957-021-02178-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Metcalfe, Christopher Muzaffar, Jameel Kulendra, Kevin Sanghera, Paul Shaw, Simon Shad, Amjad Saravanappa, Natarajan Paluzzi, Alessandro Ahmed, Shahzada Chordomas and chondrosarcomas of the skull base: treatment and outcome analysis in a consecutive case series of 24 patients |
title | Chordomas and chondrosarcomas of the skull base: treatment and outcome analysis in a consecutive case series of 24 patients |
title_full | Chordomas and chondrosarcomas of the skull base: treatment and outcome analysis in a consecutive case series of 24 patients |
title_fullStr | Chordomas and chondrosarcomas of the skull base: treatment and outcome analysis in a consecutive case series of 24 patients |
title_full_unstemmed | Chordomas and chondrosarcomas of the skull base: treatment and outcome analysis in a consecutive case series of 24 patients |
title_short | Chordomas and chondrosarcomas of the skull base: treatment and outcome analysis in a consecutive case series of 24 patients |
title_sort | chordomas and chondrosarcomas of the skull base: treatment and outcome analysis in a consecutive case series of 24 patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945343/ https://www.ncbi.nlm.nih.gov/pubmed/33750413 http://dx.doi.org/10.1186/s12957-021-02178-6 |
work_keys_str_mv | AT metcalfechristopher chordomasandchondrosarcomasoftheskullbasetreatmentandoutcomeanalysisinaconsecutivecaseseriesof24patients AT muzaffarjameel chordomasandchondrosarcomasoftheskullbasetreatmentandoutcomeanalysisinaconsecutivecaseseriesof24patients AT kulendrakevin chordomasandchondrosarcomasoftheskullbasetreatmentandoutcomeanalysisinaconsecutivecaseseriesof24patients AT sangherapaul chordomasandchondrosarcomasoftheskullbasetreatmentandoutcomeanalysisinaconsecutivecaseseriesof24patients AT shawsimon chordomasandchondrosarcomasoftheskullbasetreatmentandoutcomeanalysisinaconsecutivecaseseriesof24patients AT shadamjad chordomasandchondrosarcomasoftheskullbasetreatmentandoutcomeanalysisinaconsecutivecaseseriesof24patients AT saravanappanatarajan chordomasandchondrosarcomasoftheskullbasetreatmentandoutcomeanalysisinaconsecutivecaseseriesof24patients AT paluzzialessandro chordomasandchondrosarcomasoftheskullbasetreatmentandoutcomeanalysisinaconsecutivecaseseriesof24patients AT ahmedshahzada chordomasandchondrosarcomasoftheskullbasetreatmentandoutcomeanalysisinaconsecutivecaseseriesof24patients |